Oct. 1, 2007 - Emphasys Medical Inc. announced the submission of a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) requesting regulatory approval to market the Emphasys endobronchial valve, the Zephyr(R) EBV, in the United States. The Zephyr EBV is a minimally invasive and potentially reversible treatment option intended to help patients with emphysema breathe easier...Emphasys Medical's Press Release -
Oct 2, 2007
Emphasys Medical, PMA Submission for Bronchial Valve Therapy
Oct. 1, 2007 - Emphasys Medical Inc. announced the submission of a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) requesting regulatory approval to market the Emphasys endobronchial valve, the Zephyr(R) EBV, in the United States. The Zephyr EBV is a minimally invasive and potentially reversible treatment option intended to help patients with emphysema breathe easier...Emphasys Medical's Press Release -
